These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8103820)

  • 1. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status.
    Seremetis SV; Aledort LM; Bergman GE; Bona R; Bray G; Brettler D; Eyster ME; Kessler C; Lau TS; Lusher J
    Lancet; 1993 Sep; 342(8873):700-3. PubMed ID: 8103820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of a very high-purity factor VIII concentrate on the immune system of HIV-infected haemophiliacs: a randomized, two-year comparison with a high-purity concentrate.
    de Biasi R; Rocino A; Quirino AA; Miraglia E; Ziello L
    Haemophilia; 1996 Apr; 2(2):82-7. PubMed ID: 27214013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intermediate- and high-purity factor VIII concentrates on immune function in HIV-seropositive haemophiliacs as assessed by quantitative CD 4 counts.
    Deitcher SR; Tuller J; Dugdale M
    Haemophilia; 1997 Oct; 3(4):265-9. PubMed ID: 27214862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate.
    Mannucci PM; Gringeri A; de Biasi R; Baudo F; Morfini M; Ciavarella N
    Thromb Haemost; 1992 Mar; 67(3):310-3. PubMed ID: 1353642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purity of factor VIII concentrates and serial CD4 counts. The Transfusion Safety Study Group.
    Hilgartner MW; Buckley JD; Operskalski EA; Pike MC; Mosley JW
    Lancet; 1993 May; 341(8857):1373-4. PubMed ID: 8098792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4 cells in HIV-1 infected hemophiliacs: effect of factor VIII concentrates.
    Goldsmith JM; Deutsche J; Tang M; Green D
    Thromb Haemost; 1991 Oct; 66(4):415-9. PubMed ID: 1839091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of factor VIII concentrates of very high purity on CD4+ cell count in hemophiliacs infected with HIV].
    Molina Alejandro R; Lorenzo Herrero JI; Haya Guaita S; Querol Fuentes F; Aznar Lucea JA
    Rev Clin Esp; 1996 Jun; 196(6):365-9. PubMed ID: 8767071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological effects of intermediate purity clotting factor concentrates: failure to affect lymphocyte activation in vivo.
    Higgins JA; Giangrande PL; Kernoff PB; Goodall AH
    Br J Haematol; 1993 Feb; 83(2):296-305. PubMed ID: 8457478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate.
    de Biasi R; Rocino A; Miraglia E; Mastrullo L; Quirino AA
    Blood; 1991 Oct; 78(8):1919-22. PubMed ID: 1822966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study.
    Goedert JJ; Cohen AR; Kessler CM; Eichinger S; Seremetis SV; Rabkin CS; Yellin FJ; Rosenberg PS; Aledort LM
    Lancet; 1994 Sep; 344(8925):791-2. PubMed ID: 7916077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very-high-purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: conclusions of a prospective 3-year study. Monoclate Study Group.
    Seremetis SV
    Semin Hematol; 1993 Oct; 30(4 Suppl 5):10-3. PubMed ID: 7903480
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison.
    Hay CR; Ludlam CA; Lowe GD; Mayne EE; Lee RJ; Prescott RJ; Lee CA
    Br J Haematol; 1998 Jun; 101(4):632-7. PubMed ID: 9674733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients.
    Sabin C; Pasi J; Phillips A; Elford J; Janossy G; Lee C
    Thromb Haemost; 1994 Aug; 72(2):214-7. PubMed ID: 7831654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological studies in HIV seronegative haemophiliacs: relationships to blood product therapy.
    Cuthbert RJ; Ludlam CA; Steel CM; Beatson D; Peutherer JF
    Br J Haematol; 1992 Mar; 80(3):364-9. PubMed ID: 1581216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate.
    Allersma DP; Smid WM; van der Does JA; van der Meer J; Briët E
    Thromb Haemost; 1996 Feb; 75(2):261-6. PubMed ID: 8815573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High versus ultra-high purity factor VIII concentrate therapy: prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs.
    Varon D; Schulman S; Dardik R; Barzilai A; Bashari D; Martinowitz U
    Thromb Haemost; 1994 Sep; 72(3):359-62. PubMed ID: 7855784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evolution of CD4 and CD8 lymphocyte subsets in HIV seronegative and seropositive hemophiliacs].
    Lorenzo JI; Molina R; Aznar JA
    Sangre (Barc); 1993 Feb; 38(1):5-11. PubMed ID: 8470035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The course of preexistent immune abnormalities in HIV negative haemophiliacs treated for two years with a monoclonal purified factor VIII concentrate.
    Smid WM; van der Meer J; Smit JW; Halie MR
    Thromb Haemost; 1993 Apr; 69(4):306-10. PubMed ID: 8388579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.
    Mannucci PM; Brettler DB; Aledort LM; Lusher JM; Abildgaard CF; Schwartz RS; Hurst D
    Blood; 1994 Apr; 83(7):1958-62. PubMed ID: 7908234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective clinical trial of high-purity factor VIII preparations in haemophiliacs.
    Varon D
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S82-3. PubMed ID: 7495975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.